Journal of AIDS & Clinical Research

Baker JV

Publications

• Research Article
  Switching from Abacavir/Lamivudine to Tenofovir DF/Emtricitabine Reduces Biomarkers of Inflammation: A Randomized Proof of Concept Study
  Author(s): Alozie O, Prosser R, Huppler Hullsiek K, Duprez D, Rhame F, Henry WK and Baker JVAlozie O, Prosser R, Huppler Hullsiek K, Duprez D, Rhame F, Henry WK and Baker JV
  
  Background: Abacavir use has been associated with cardiovascular disease (CVD) risk, but this effect has not been consistent across studies. Methods: To explore abacavir-related CVD risk we studied 27 HIV-positive participants taking fixed-dose abacavir/ lamivudine-based antiretroviral therapy (ART) with viral suppression and randomized them to remain on their current regimen (n=13) or switch the nucleoside component to tenofovir disoproxil fumarate (DF)/emtricitabine (n=14). Plasma biomarkers were measured at baseline and at 1 and 6 months. Results: At baseline, median (IQR) age was 46 years (41-53) and CD4+ count 620 cells/mm3 (477-836). There were no baseline differences in individual CVD risk factors between groups, however, 10-year Framingham Risk Score (FRS) trended higher for those taking abacavir (8.5%) versus tenofovir DF (4.7%). Switching to a tenofovir DF-ba.. Read More»
  DOI: 10.4172/2155-6113.1000278

  Abstract PDF